JP2001508643A5 - - Google Patents

Download PDF

Info

Publication number
JP2001508643A5
JP2001508643A5 JP1997533941A JP53394197A JP2001508643A5 JP 2001508643 A5 JP2001508643 A5 JP 2001508643A5 JP 1997533941 A JP1997533941 A JP 1997533941A JP 53394197 A JP53394197 A JP 53394197A JP 2001508643 A5 JP2001508643 A5 JP 2001508643A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997533941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001508643A (ja
Filing date
Publication date
Priority claimed from DE19653445A external-priority patent/DE19653445C1/de
Application filed filed Critical
Priority claimed from PCT/DE1997/000643 external-priority patent/WO1997035873A2/de
Publication of JP2001508643A publication Critical patent/JP2001508643A/ja
Publication of JP2001508643A5 publication Critical patent/JP2001508643A5/ja
Ceased legal-status Critical Current

Links

JP53394197A 1996-03-26 1997-03-26 抗増殖特性を有するペプチド Ceased JP2001508643A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19611939 1996-03-26
DE19611939.1 1996-03-26
DE19653445A DE19653445C1 (de) 1996-03-26 1996-12-20 Peptide mit antineoplastischen Eigenschaften
DE19653445.3 1996-12-20
PCT/DE1997/000643 WO1997035873A2 (de) 1996-03-26 1997-03-26 Peptide mit antiproliferativen eigenschaften

Publications (2)

Publication Number Publication Date
JP2001508643A JP2001508643A (ja) 2001-07-03
JP2001508643A5 true JP2001508643A5 (enExample) 2004-12-02

Family

ID=26024147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53394197A Ceased JP2001508643A (ja) 1996-03-26 1997-03-26 抗増殖特性を有するペプチド

Country Status (10)

Country Link
US (1) US6660830B1 (enExample)
EP (1) EP0892811B1 (enExample)
JP (1) JP2001508643A (enExample)
CN (1) CN1214694A (enExample)
AT (1) ATE229977T1 (enExample)
AU (1) AU727662B2 (enExample)
BR (1) BR9711795A (enExample)
CA (1) CA2251691A1 (enExample)
NO (1) NO984415L (enExample)
WO (1) WO1997035873A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005108416A2 (en) * 2004-04-21 2005-11-17 The University Of Chicago Myosin light chain kinase inhibitors and their use
US7947645B2 (en) * 2004-09-02 2011-05-24 Cognosci, Inc. APO E analogs and methods for their use
CA2600370A1 (en) 2005-03-14 2006-09-14 Board Of Regents Of The University Of Texas System Bioactive fus1 peptides and nanoparticle-polypeptide complexes
KR100729830B1 (ko) * 2005-03-24 2007-06-19 바이오스펙트럼 주식회사 페너트라틴을 이용하여 단백질의 세포투과를 증진시키는대장균용발현벡터
US9243035B2 (en) * 2013-11-26 2016-01-26 Nymox Corporation Peptides effective in the treatment of conditions requiring the removal or destruction of cells
US10513711B2 (en) 2014-08-13 2019-12-24 Dupont Us Holding, Llc Genetic targeting in non-conventional yeast using an RNA-guided endonuclease
WO2016073433A1 (en) 2014-11-06 2016-05-12 E. I. Du Pont De Nemours And Company Peptide-mediated delivery of rna-guided endonuclease into cells
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
DK4144844T3 (da) 2015-10-12 2025-11-24 Dupont Us Holding Llc Beskyttede dna-templates til genmodificering og øget homolog rekombination i celler og fremgangsmåder til anvendelse deraf
AU2016341044B2 (en) 2015-10-20 2023-03-09 Pioneer Hi-Bred International, Inc. Restoring function to a non-functional gene product via guided Cas systems and methods of use
BR112018007796A2 (pt) 2015-11-06 2018-10-30 Du Pont plantas de soja, partes de plantas de soja ou sementes de soja, método para selecionar uma célula de soja, métodos de seleção de uma célula de soja e de produção de um locus e molécula de ácido nucleico
WO2017155714A1 (en) 2016-03-11 2017-09-14 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
KR20190016970A (ko) 2016-06-14 2019-02-19 파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 식물 게놈 변형을 위한 cpf1 엔도뉴클레아제의 용도
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US20190100745A1 (en) 2016-06-20 2019-04-04 Pioneer Hi-Bred International, Inc. Novel cas systems and methods of use
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US11519009B2 (en) 2017-01-09 2022-12-06 University Of Massachusetts Complexes for gene deletion and editing
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
KR102705104B1 (ko) 2017-12-15 2024-09-09 다니스코 유에스 인크. Cas9 변이체 및 사용 방법
US12084676B2 (en) 2018-02-23 2024-09-10 Pioneer Hi-Bred International, Inc. Cas9 orthologs
WO2020123887A2 (en) 2018-12-14 2020-06-18 Pioneer Hi-Bred International, Inc. Novel crispr-cas systems for genome editing
CA3136114A1 (en) 2019-04-05 2020-10-08 Danisco Us Inc. Methods for integrating a donor dna sequence into the genome of bacillus using linear recombinant dna constructs and compositions thereof
KR20210148270A (ko) 2019-04-05 2021-12-07 다니스코 유에스 인크. 이중 원형 재조합 dna 작제물 및 이의 조성물을 이용하여 바실러스의 게놈 내로의 폴리뉴클레오타이드를 통합하기 위한 방법
WO2024118882A1 (en) 2022-12-01 2024-06-06 Genencor International Bv Iterative multiplex genome engineering in microbial cells using a selection marker swapping system
EP4627076A1 (en) 2022-12-01 2025-10-08 Danisco Us Inc Iterative multiplex genome engineering in microbial cells using a recombinant self-excisable selection marker system
WO2024118881A1 (en) 2022-12-01 2024-06-06 Genencor International Bv Iterative muliplex genome engineering in microbial cells using a bidirectional selection marker system
CN121152874A (zh) 2023-03-20 2025-12-16 先锋国际良种公司 具有改变的PAM识别的Cas多肽

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851991A (en) * 1987-08-31 1998-12-22 The Regents Of The University Of California Therapeutic use of the retinoblastoma susceptibility gene product
EP0398955B1 (en) * 1988-01-21 1998-07-08 MASSACHUSETTS EYE & EAR INFIRMARY Diagnosis of retinoblastoma
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
IL106760A (en) * 1992-08-25 1999-12-31 Miles Inc Protein-nucleic acid hybrid construct for translocating an exogenous nucleic acid into a target cell and nucleus
DE4237129A1 (de) * 1992-11-03 1994-05-05 Radulescu Razvan Tudor Dr Med Anwendung der Komplementärpeptid-Theorie in der Onkologie/Kartiologie: 1. VPH = NH¶2¶-len alphaN-Me-Phe Tyr Lys alphaN-Me-Lys Val D-Tyr-COOH 2. Kalziumantagonist auf der Basis eines Komplementärpeptides zur Calmodulinbindungsstelle 3.hSNI¶B¶¶1¶¶6¶¶-¶¶2¶¶1¶[3'->5'] = NH¶2¶-Len Pro Thr His Asp Ala-COOH
US5625031A (en) * 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
EP0685493A1 (en) * 1994-06-01 1995-12-06 CANJI, Inc. Tumor suppressor fusion proteins
WO1995034647A1 (en) * 1994-06-13 1995-12-21 Vanderbilt University Compositions for and methods of enhancing delivery of nucleic acids to cells
US5573925A (en) * 1994-11-28 1996-11-12 The Wistar Institute Of Anatomy And Biology P53 proteins with altered tetramerization domains
DE19526174C2 (de) * 1995-07-18 1998-02-26 Friedhelm Prof Dr Herrmann Mittel gegen Tumorwachstum

Similar Documents

Publication Publication Date Title
JP2000501599A5 (enExample)
JP2000501018A5 (enExample)
JP2000500076A5 (enExample)
JP2000516511A5 (enExample)
JP2000507909A5 (enExample)
JP2000501324A5 (enExample)
JP2000500055A5 (enExample)
JP2000508006A5 (enExample)
JP2000500026A5 (enExample)
JP2001502204A5 (enExample)
JP2000502472A5 (enExample)
JP2000501338A5 (enExample)
JP2000500874A5 (enExample)
JP2002502549A5 (enExample)
JP2000502425A5 (enExample)
JP2000502485A5 (enExample)
JP2000502568A5 (enExample)
JP2000500912A5 (enExample)
JP2000502570A5 (enExample)
JP2001523981A5 (enExample)
JP2000501229A5 (enExample)
JP2000500857A5 (enExample)
JP2000502316A5 (enExample)
JP2000502714A5 (enExample)
JP2001508643A5 (enExample)